Bimatoprost cutaneous solution 0.03% — Competitive Intelligence Brief

Bimatoprost cutaneous solution 0.03% (Bimatoprost cutaneous solution 0.03%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog. Area: Ophthalmology.

phase 2 Prostaglandin analog FP receptor Ophthalmology Small molecule

Target snapshot

Bimatoprost cutaneous solution 0.03% (Bimatoprost cutaneous solution 0.03%) — Allergan. Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bimatoprost cutaneous solution 0.03% TARGET	Bimatoprost cutaneous solution 0.03%	Allergan	phase 2	Prostaglandin analog	FP receptor
Generic latanoprost	Generic latanoprost	CHU de Quebec-Universite Laval	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
tafluprost/timolol	tafluprost/timolol	Fondazione G.B. Bietti, IRCCS	marketed	Prostaglandin analog / beta-blocker combination	FP receptor (tafluprost); beta-2 adrenergic receptor (timolol)
travoprost 0.004% (drug)	travoprost 0.004% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Preservative-free latanoprost	Preservative-free latanoprost	Association for Innovation and Biomedical Research on Light and Image	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Co-Latanoprost	Co-Latanoprost	Dr. David Yan	marketed	Prostaglandin analog combination	FP receptor (prostaglandin F receptor)
Preservative-free latanoprost 50µg/ml	Preservative-free latanoprost 50µg/ml	Medical University of Vienna	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog class)

1. Allergan · 3 drugs in this class
2. AbbVie · 2 drugs in this class
3. Bnai Zion Medical Center · 1 drug in this class
4. Ibis Reproductive Health · 1 drug in this class
5. Ocuwize LTD · 1 drug in this class
6. Shaare Zedek Medical Center · 1 drug in this class
7. University Medical Centre Maribor · 1 drug in this class
8. University of North Carolina, Chapel Hill · 1 drug in this class
9. University of Pennsylvania · 1 drug in this class
10. Wolfson Medical Center · 1 drug in this class